Squarepoint’s Imunon IMNN Stock Holding History

Squarepoint’s Portfolio IMNN Stock Details IMNN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-530	Closed	-$143K	–	3449
2021 Q1	$143K	Sell	530 -149	-22%	-$50.1K	﹤0.01%	2812
2020 Q4	$94K	Buy	+679	New	+$81.4K	﹤0.01%	2731

Other funds holding IMNN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eudaimonia Partners Winchester, Tennessee $420M AUM 27.21% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Squarepoint's IMNN Position: Q2 2021 in Review

Squarepoint sold out of Imunon (IMNN) in Q2 2021, closing a stake of 530 shares — an estimated $143K sold.

Squarepoint first reported a position in IMNN in Q4 2020 and held it in 2 quarters. The position peaked at $143K in Q1 2021. 37 funds tracked by Wall St. Rank hold IMNN as of Q2 2021.

Squarepoint reported no remaining Imunon position as of Q2 2021 after selling out during the quarter.
Squarepoint sold 530 Imunon shares in Q2 2021, an estimated $143K.
Squarepoint first reported a position in Imunon in Q4 2020 and held it in 2 quarters.
Squarepoint's Imunon position peaked at $143K in Q1 2021.
37 funds tracked by Wall St. Rank held Imunon as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.